Barbora Velacková

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Spyridon Gkalpakiotis, Petra Cetkovská, Petr Arenberger et al. · Dermatology and Therapy · 2021 · 47 citations · Full text

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Martina Kojanová, Jan Hugo, Barbora Velacková et al. · Journal of Dermatological Treatment · 2022 · 31 citations

Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes

Jiří Kubeš, Alexandra Haas, Vladimír Vondráček et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 18 citations

Radiation Medicine, Nuclear Medicine, Radiation Therapy +9

Efficacy of switches within the class of <scp>IL</scp> ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( <scp>BIOREP</scp> )

M Tichý, Martina Kojanová, Barbora Velacková et al. · Dermatologic Therapy · 2022 · 11 citations